HELP · Cybin Inc. · Stock research

Current Thesis

The narrative leg here is thin. A clinical-stage CNS microcap ran a parabolic, social-velocity-driven melt-up into a blowoff RSI reading in the mid-90s, then priced a dilutive secondary 10.3M shares at $4.85 on 2026-06-24 into that strength. The only durable, underwritable event is the APPROACH Phase 3 trial of HLP003 for adjunctive major depressive disorder, which only just began enrolling and reads out quarters-to-years from now. What moved the tape was flow rather than fundamentals; momentum is setting the quote while the pipeline stays far from any data. This is a mean-reversion candidate off a vertical spike, so the sensible stance is to wait for a base rather than chase.

Bullish and bearish views on Cybin Inc.

The model's bull view on Cybin Inc. (HELP), in brief: 2026-06-24: Priced a 10.3M-share underwritten offering at $4.85 (~$50M gross), giving the company runway to actually run the APPROACH Phase 3 and removing the single biggest overhang for a pre-revenue CNS developer financing risk. The bear view: The move that put HELP on the radar was a social-velocity spike, not a data event. Both cases follow in full.

Bull Case

• 2026-06-24: Priced a 10.3M-share underwritten offering at $4.85 (~$50M gross), giving the company runway to actually run the APPROACH Phase 3 and removing the single biggest overhang for a pre-revenue CNS developer financing risk.
• 2026-06-24: APPROACH Phase 3 of HLP003 (adjunctive MDD) is now enrolling. Adjunctive depression is a large addressable market, and next-gen-antidepressant names have repeatedly drawn premium multiples on Phase 2→3 transitions.
• 2026-07-01: Canaccord Genuity maintains Buy; even after trimming the target to $42, that models substantial NPV on trial success against a sub-$5 clearing price the sell-side is underwriting a heavily skewed payoff.
• 2026-06-29: Fiscal Q4 EPS printed $(0.85) versus the $(1.11) estimate a narrower-than-expected loss, consistent with disciplined pre-Phase-3 spend.

Bear Case

• The move that put HELP on the radar was a social-velocity spike, not a data event. Parabolic microcaps that print RSI in the 90s mean-revert hard once the flow rotates out.
• The 2026-06-24 dilution is management monetizing the melt-up: issuing 10.3M new shares at $4.85 into a spike enlarges the float and hands supply to holders at a price the company itself validated as fair a ceiling, not a springboard.
• There is no near-term catalyst. APPROACH just began enrollment; a Phase 3 depression readout is a multi-year event, and nothing dated inside 30 days can sustain the momentum once attention fades.
• The gap between a $42 sell-side target and a $4.85 equity clearing price is not free upside; it reflects the market pricing a high probability the binary fails.
• Micro float plus heavy retail ownership means violent two-way volatility and thin liquidity a stop can gap through in a single session.

Setup & Price Structure

The tape is post-blowoff. RSI pushed into the mid-90s on the melt-up, a reading that historically precedes cooling or reversal rather than continuation. The 2026-06-24 secondary at $4.85 is now the reference level that matters it is where the company and institutional buyers agreed to transact size. A hold above that shelf on a pullback, with volume drying up and the RSI resetting toward the 40s-60s, would be the first evidence of a tradable base. A close back below $4.85 puts the offering buyers underwater and confirms the vertical move has unwound. No higher-low structure exists yet; the chart is a single vertical spike, which is the opposite of an entry.

Catalyst Calendar (next 30 days)

• No dated, market-moving catalyst inside 30 days. APPROACH Phase 3 (HLP003, adjunctive MDD) is in early enrollment; interim or topline data is quarters-to-years out.
• Watch for additional shelf takedowns or ATM activity a just-completed raise does not preclude another if the stock stays elevated.

Elapsed catalysts

• 2026-06-29 fiscal Q4 print is already in the tape; the next fiscal update is the following quarterly report (est. ~2026-09, unconfirmed). _(passed 16d ago)_

What Would Change Our Mind

A constructive re-rating needs the price action to build a real base above the $4.85 secondary shelf: a higher low, a volume-backed reclaim, and an RSI reset rather than another vertical push. Alternatively, a dated, credible catalyst (a defined interim analysis, a partnership, a regulatory milestone) would convert this from a flow-driven melt-up into an underwritable narrative. Absent either, elevated price with fading social velocity is a mean-reversion setup, not an entry.

Correlation Notes

HELP moves with the psychedelic and next-gen-CNS-therapeutics cohort and with the broader small-cap clinical-stage biotech tape (XBI as the read-through). Its dominant driver right now, though, is idiosyncratic retail flow, so beta to the group is loose. In risk-off rotations, unprofitable microcap biotech is sold first; in risk-on, social-velocity names like this one can decouple upward violently. The 2026-06-24 dilution is name-specific and does not read across to peers.